The EGFR-NSCLC pipeline possesses some drugs in late-stage development to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment, including Zipalertinib (CLN-081) (Cullinan Oncology/Taiho Pharma), Firmonertinib (ArriVent BioPharma), Ivonescimab (SMT112) (Akeso Biopharma/Summit Therapeutics), PF-08046054 (Pfizer), Patritumab Deruxtecan (Daiichi Sankyo/AstraZeneca), Sacituzumab Tirumotecan (MK-2870) (Merck/Kelun-Biotech), SYS6010 (CSP

BHV-8100 is an orally administered, brain-penetrant PKM2 modulator; a novel therapeutic class addressing the bioenergetic and immunometabolic basis of systemic and central nervous system disorders First-in-human study initiated with dose escalation ongoing; preliminary data in healthy participants demonstrates favorable pharmacokinetics supporting convenient, once-daily dosing and well a tolerated profile at projected therapeutic exposures Penetrates blood-brain barrier and reverses metabolic

Expanding in the metabolic space, Eli Lilly has struck a back-loaded licensing deal with South Korea’s Hanmi Pharm for a mid-stage GLP-2 agonist being trialed for short bowel syndrome. Eli Lilly’s late-spring dealmaking spree shows no sign of stopping as the pharma giant stuck a licensing agreement with South Korean biotech Hanmi Pharm worth up to $1.2 billion for access to a potential next wave of metabolic drugs. Under the deal, Lilly will help develop Hanmi’s Phase 2 GLP-2 agonist sonefpegl

Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced the closing of a $30 million Series A financing from RA Capital Management, LP (“RA Capital”), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital was the sole investor in the financing. The Series A financing will support comp

June 2, 2026 -- Tavo Biotherapeutics today announced the successful closing of a $17 million Series A financing led by Pureos Bioventures with participation by Polaris Partners and continued support from existing investor Tau Capital. The proceeds will be used to advance Tavo's pipeline of innovative therapies targeting glaucoma and retinal disease. In conjunction with the financing, Tavo Biotherapeutics also announced the appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer, t

While a regimen involving Pfizer's Talzenna (talazoparib) and androgen receptor pathway inhibitor Xtandi (enzalutamide) is already approved for patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), the pharma is looking to move the duo into a new population — metastatic castration-sensitive prostate cancer (mCSPC), also known as metastatic hormone-sensitive prostate cancer — and now it has the data to back up its ambitions. At

Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease Consistent responses observed across atypical EGFR mutation subgroups, including those historically associated with poorer outcomes ASCO 2026 results reinforce the significance of RYBREVANT®-based regimens for patients across EGFR mutations May 29, 2026 -- Johnson & Johnson (NYSE:JNJ) today announced updated results from the Phase 1/1b CHRYS

Anthropic has raised $65 billion in Series H funding, bringing its post-money valuation to $965 billion and surpassing OpenAI to become the world's highest-valued private AI company. Altimeter Capital, Dragoneer, Greenoaks, Sequoia Capital, Capital Group, Coatue, D1 Capital Partners, GIC, ICONIQ and XN co-led the round. Other investors in the round include AMP PBC, Baillie Gifford, Blackstone, Brookfield, D.E. Shaw Ventures, DST Global, Fidelity Management & Research Company, General Catalyst,

Pfizer continues its dealmaking spree by striking a back-heavy partnership with China’s Innovent Biologics to assemble a pipeline of antibody-based therapies for cancer. Pfizer is teaming up with China’s Innovent Biologics to advance a broad pipeline of cancer therapies, continuing the New York pharma’s recent dealmaking spree. Under the terms of the agreement, announced late on Thursday, Pfizer will make a $650 million upfront payment and offer up to $9.85 billion in development, regulatory a

Financing Provides Immediate Growth Capital to Support Clinical Development Initiatives and Extends Projected Operating Cash Runway for Over Two (2) Years May 28, 2026 -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced that it has entered into a definitive financing agreement with an institutional investor providing for